The effects of drugs on human models of emotional processing: An account of antidepressant drug treatment

Dialogues in Clinical Neuroscience

Volumn 17, Issue 4, 2015, Pages 477-487

  Pringle, Abbie ^a   Harmer, Catherine J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antidepressant; Anxiety; Depression; Emotional processing; Healthy volunteer; Selective serotonin reuptake inhibitor

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; MONOAMINE;

ANTIDEPRESSANT ACTIVITY; AROUSAL; ARTICLE; DEPRESSION; DRUG EFFECT; EMOTION; EMOTIONAL MEMORY; FACIAL EXPRESSION; FACIAL RECOGNITION; HUMAN; MEMORY; MOOD CHANGE; AFFECT; ANIMAL; DEPRESSIVE DISORDER; DRUG EFFECTS; PHYSIOLOGY;

AFFECT; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DEPRESSIVE DISORDER; EMOTIONS; HUMANS; MEMORY;

EID: 84958950657     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122(5):509-522.
2. Marshall EF, Stirling GS, Tait AC, Todrick A. The effect of iproniazid and imipramine on the blood platelet 5-hydroxytrptamine level in man. Br J Pharmacol Chemother. 1960;15:35-41.
3. Glowinski J, Axelrod J. Inhibition of uptake of tritiated-noradrenaline in the intact rate brain by imipramine and structurally related compounds. Nature. 1964;204:1318-1319.
4. Coppen A. The biochemistry of affective disorders. Brit J Psychiatry. 1967;113(504):1237-1264.
5. Sharp T, Cowen PJ. 5-HT and depression: is the glass half-full? Curr Opin Pharmacol. 2011;11(1):45-51.
6. Crockett MJ, Clark L, Roiser JP, et al. Converging evidence for central 5-HT effects in acute tryptophan depletion. Mol Psychiatry. 2012;17(2):121-123.
7. Ruhé HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry. 2007;12(4):331-359.
8. Frazer A, Benmansour S. Delayed pharmacological effects of antidepressants. Mol Psychiatry. 2002(7):S23-S28.
9. Castrén E, Hen R. Neuronal plasticity and antidepressant actions. Trends Neurosci. 2013;36(5):259-267.
10. Harmer C, Goodwin G, Cowen P. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry. 2009;195(2):102-108.
11. Roiser J, Elliott R, Sahakian B. Cognitive mechanisms of treatment in depression. Neuropsychopharmacology. 2012;37(1):117-136.
12. Elliott R, Zahn R, Deakin W, Anderson I. Affective cognition and its disruption in mood disorders. Neuropsychopharmacology. 2011;36(1):153-182.
13. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive Therapy of Depression. New York, NY: Guilford; 1979.
14. Mathews A, MacLeod C. Cognitive vulnerability to emotional disorders. Annu Rev Clin Psychol. 2005;1:167-195.
15. Williams JMG, Watts FN, MacLeod C, Mathews A. Cognitive Psychology and Emotional Disorders. Oxford, UK: John Wiley and Sons; 1988.
16. Bradley BP, Mathews A. Negative self-schemata in clinical depression. Br J Clin Psychol. 1983;22:173-181.
17. MacLeod C, Rutherford E, Campbell L, Ebsworthy G, Holker L. Selective attention and emotional vulnerability: assessing the causal basis of their association through the experimental manipulation of attentional bias. J Abnorm Psychol. 2002;111:107-123.
18. Harmer C, O'Sullivan U, Favaron E, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry. 2009;166(10):1178-1184.
19. Tranter R, Bell D, Gutting P, Harmer C, Healy D, Anderson I. The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients. J Affect Disord. 2009;118(1-3):87-93.
20. Godlewska BR, Browning M, Norbury R, Cowen PJ, Harmer CJ. Early changes in neural response to emotional stimuli predict clincial reponse to ssri treatment in depression. J Psychopharmacol. 2014;28(8 Abstract Supplement):Abstract.
21. Shiroma PR, Thuras P, Johns B, Lim KO. Emotion recognition processing as an early predictor of response to 8-week citalopram treatment in late-life depression. Int J Geriatr Psychiatry. 2014;29(11):1132-1139.
22. Berton O, Hahn C-G, Thase ME. Are we getting closer to valid translational models for major depression? Science. 2012;338(6103):75-79.
23. Bower GH. Mood and memory. Am Psychol. 1981;36(2):129-148.
24. Gotlib IH, Joormann J. Cognition and depression: current status and future directions. Annu Rev Clin Psychol. 2010;6:285-312.
25. Harmer C, Shelley N, Cowen P, Goodwin G. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry. 2004;161(7):1256-1263.
26. Browning M, Grol M, Ly V, Goodwin G, Holmes E, Harmer C. Using an experimental medicine model to explore combination effects of pharmacological and cognitive interventions for depression and anxiety. Neuropsychopharmacology. 2011;36(13):2689-2697.
27. Harmer C, Hill S, Taylor M, Cowen P, Goodwin G. Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. Am J Psychiatry. 2003;160(5):990-992.
28. Browning M, Reid C, Cowen PJ, Goodwin GM, Harmer CJ. A single dose of citalopram increases fear recognition in healthy subjects. J Psychopharmacol. 2007;21(7):684-690.
29. Brown GW, Harris T. Social Origins of Depression. London, UK: Tavistock Publications; 1978.
30. Gotlib IH, Asarnow RF. Interpersonal and impersonal problem-solving skills in midly and clincially depressed university students. J Consult Clin Psychol. 1979;47(1):86-95.
31. Dalili MN, Penton-Voak IS, Harmer CJ, Munafo MR. Meta-analysis of emotion recognition deficites in major depressive disorder. Psychol Med. 2015;45(6):1135-1144.
32. Harmer CJ, Bhagwagar Z, Perrett DI, Völlm BA, Cowen PJ, Goodwin GM. Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology. 2003;28(1):148-152.
33. Kent JM, Coplan JD, Gorman JM. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry. 1998;44(9):812-824.
34. Graeff FG, Guimaraes FS, De Andrade TGCS, Deakin JFW. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav. 1996;54(1):129-141.
35. Di Simplicio M, Doallo S, Costoloni G, Rohenkohl G, Nobre AC, Harmer CJ. 'Can you look me in the face?' Short-term SSRI administration reverts avoidant ocular face exploration in subjects at risk for psychopathology. Neuropsychopharmacology. 2014;39(13):3059-3066.
36. Jonassen R, Chelnokova O, Harmer CJ, Leknes S, Landro NI. A single dose of antidepressant alters eye-gaze patterns across face stimuli in healthy women. Psychopharmacology. 2015;232(5):953-958.
37. Heine SJ, Lehman DR, Markus HR, Kitayama S. Is there a universal need for positive self-regard? Psychol Rev. 1999;106(4):766-794.
38. Harmer CJ, Heinzen J, O'Sullivan U, Ayres RA, Cowen PJ. Dissociable effects of acute antidepressant drug administration on subjective and emotional processing measures in healthy volunteers. Psychopharmacology. 2008;199(4):495-502.
39. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008;213(1-2):93-118.
40. Harmer C, Cowen P, Goodwin G. Efficacy markers in depression. J Psychopharmacol. 2011;25(9):1148-1158.
41. Disner SG, Beevers CG, Haigh EA, Beck AT. Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci. 2011;12(8):467-477.
42. Adolphs R. Social cognition and the human brain. Trends Cogn Sci. 1999;3(12):469-479.
43. Drevets WC, Raichle ME. Neuroanatomical circuits in depression: implications for treatment mechanisms. Psychopharmacol Bull. 1992;28(3):261-274.
44. Fu C, Williams S, Cleare A, et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry. 2004;61(9):877-889.
45. Victor TA, Furey ML, Fromm SJ, Ohman A, WC. D. Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. Arch Gen Psychiatry. 2010;67(11):1128-1134.
46. Godlewska BR, Norbury R, Selvaraj S, Cowen PJ, Harmer CJ. Shortterm SSRI treatment normalises amygdala hyperactivity in depressed patients. Psychol Med. 2012;41(12):2609-2617.
47. Harmer C, Mackay C, Reid C, Cowen P, Goodwin G. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry. 2006;59(9):816-820.
48. Norbury R, Mackay C, Cowen P, Goodwin G, Harmer C. Short-term antidepressant treatment and facial processing. Functional magnetic resonance imaging study. Br J Psychiatry. 2007;190(6):531-532.
49. Arce E, Simmons A, Lovero K, Stein M, Paulus M. Escitalopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology. 2008;196:661-672.
50. Windischberger C, Lanzenberger R, Holik A, et al. Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. NeuroImage. 2010;49(2):1161-1170.
51. Norbury R, Taylor M, Selvaraj S, Murphy S, Harmer C, Cowen P. Shortterm antidepressant treatment modulates amygdala response to happy faces. Psychopharmacology. 2009;206(2):197-204.
52. Bigos KL, Pollock BG, Aizenstein HJ, Fisher PM, Bies RR, Hariri AR. Acute 5-HT reuptake blockade potentiates human amygdala reactivity. Neuropsychopharmacology. 2008;33(13):3221-3225.
53. Murphy S, Norbury R, O'Sullivan U, Cowen P, Harmer C. Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry. 2009;194(6):535-540.
54. Murphy S. Using functional neuroimaging to investigate the mechanisms of action of selective serotonin reuptake inhibitors (SSRIs). Curr Pharm Des. 2010;16(18):1990-1997.
55. Ma Y. Neuropsychological mechanism underlying antidepressant effect:a systematic meta-analysis. Mol Psychiatry. 2014;20(3):311-317.
56. Ma Y, Li B, Wang C, Zhang W, Rao Y, Han S. Allelic varation in 5-HTTLPR and the effects of citalopram on the emotional neural network. Br J Psychiatry. 2015;206(5):385-92.
57. Ruhé HG, Koster M, Booij J, van Herk M, Veltman DJ, Schene AH. Occupancy of serotonin transporters in the amygdala by paroxetine in association with attenuation of left amygdala activation by negative faces in major depressive disorder. Psychiatry Res. 2014;221(2):155-161.
58. Murphy SE, Downham C, Cowen PJ, Harmer CJ. Direct effects of diazepam on emotional processing in healthy volunteers. Psychopharmacology. 2008;199(4):503-513.
59. Grillon C, Levenson J, Pine D. A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: a fear-potentiated startle study. Neuropsychopharmacology. 2007;32(1):225-231.
60. Browning M, Holmes EA, Harmer CJ. The modification of attentional bias to emotional information: A review of the techniques, mechanisms, and relevance to emotional disorders. Cogn Affect Behav Neurosci. 2010;10(1):8-20.
61. Gotlib IH, Kasch KL, Traill SK, Joormann J, Arnow BA, Johnson SL. Coherence and specificity of information processing biases in depression and social phobia. J Abnorm Psychol. 2004;113:386-398.
62. Murphy S, Yiend J, Lester K, Cowen P, Harmer C. Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers. Int J Neuropsychopharmacol. 2009;12(2):169-179.
63. Coupland NJ, Singh AJ, Sustrik RA, Ting P, Blair RJ. Effects of diazepam on facial emotion recognition. J Psychiatry Neurosci. 2003;28(6):452-463.
64. Arnone D, Horder J, Cowen PJ, Harmer CJ. Early effects of mirtazapine on emotional processing. Psychopharmacology. 2009;203(4):685-691.
65. Rawlings N, Norbury R, Cowen P, Harmer C. A single dose of mirtazapine modulates neural responses to emotional faces in healthy people. Psychopharmacology. 2010;212(4):625-634.
66. Harmer C, de Bodinat C, Dawson G, et al. Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. J Psychopharmacol. 2011;25(9):1159-1167.
67. Chandra P, Hafizi S, Massey-Chase RM, Goodwin GM, Cowen PJ, Harmer CJ. NK1 receptor antagonism and emotional processing in healthy volunteers. J Psychopharmacol. 2010;24(4):481-487.
68. Pringle A, McTavish S, Williams C, Smith R, Cowen P, Harmer C. Shortterm NK1 receptor antagonism and emotional processing in healthy volunteers. Psychopharmacology. 2011;215(2):239-246.
69. Pringle A, Parsons L, Cowen L, McTavish S, Cowen P, Harmer C. Using an experimental medicine model to understand the antidepressant potential of the N-Methyl-D-aspartic acid (NMDA) receptor antagonist memantine. J Psychopharmacol. 2012;26(11):1417-1423.
70. Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids. 2006;31(3):251-272.
71. Kramer MS, Winokur A, Kelsey J, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology. 2004;29(2):385-392.
72. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998;281(5383):1640-1645.
73. Keller M, Montgomery S, Ball W, et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry. 2006;59(3):216-223.
74. Harmer CJ, Dawson GR, Dourish CT, et al. Combined NK1 antagonism and serotonin reuptake inhibition: effects on emotional processing in humans. J Psychopharmacol. 2013;27(5):435-443.
75. Hayward G, Goodwin GM, Cowen PJ, Harmer CJ. Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms. Biol Psychiatry. 2005;57(5):517-524.
76. Horder J, Browning M, Di Simplicio M, Cowen P, Harmer C. Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing. J Psychopharmacol. 2012;26(1):125-132.
77. Horder J, Cowen P, Di Simplicio M, Browning M, Harmer C. Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers. Psychopharmacology. 2009;205(1):85-91.
78. Critchley HD, Lewis PA, Orth M, et al. Vagus nerve stimulation for treatment-resistant depression: behavioral and neural effects on encoding negative material. Psychosom Med. 2007;69(2):17-22.
79. Malcolm CP, Cowen PJ, Harmer CJ. High-density negative ion treatment increases positive affective memory. Psychol Med. 2009;39(11):1930-1932.
80. Pringle A, McCabe C, Cowen PJ, Harmer CJ. Antidepressant treatment and emotional processing: can we dissociate the roles of serotonin and noradrenaline? J Psychopharmacol. 2013;27(8):719-731.
81. Nutt D, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol. 2007;21(5):461-471.
82. Williams LM, Korgaonkar MS, Song YC, et al. Amygdala reactivity to emotional faces in the prediction of general and medication-specific responses to antidepressant treatment in the randomized iSPOT-D trial. Neuropsychopharmacology. 2015;40(10):2398-2408.
83. Murrough JW. Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharmacol Ther. 2012;91(2):303-309.
84. Drevets WC, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry. 2010;67(5):432-438.
85. Deakin JW, Williams S, Downey D, et al. PharmacoMRI and cognitive effects of the low-trapping NMDA channel blocker AZD6765 compared with ketamine in untreated major depressive disorder. Abstract presented at: 28th CINP World Congress of Neuropsychopharmacology. Stockholm, Sweden, 2012.
86. Stuart SA, Butler P, Munafo MR, Nutt DJ, Robinson E. Distinct neuropsychological mechanisms may explain delayed- versus rapid-onset antidepressant efficacy. Neuropsychopharmacology. 2015;40(9):2165-2174.